n INTRODUCTION
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease involving musculoskeletal structures such as joints, entheses, the synovial sheaths of tendons and the axial skeleton together with the skin and nails and showing different clinical phenotypes and course (1) . In 2006, a new designation has been proposed with the aim to cover all these clinical situations: psoriatic disease (2) . In earlier times, PsA was considered a mild disease. In the last three decades, evidence has been collected that PsA is erosive and deforming in 40-60% of patients with joint damage emerging in the first years of the disease onset (3) (4) (5) (6) (7) (8) . Patients with PsA suffer from diminished quality of life (QoL) and functional impairment and have a significant escalation in mortality compared to the general population (9, 10) . Therapies for PsA have been insufficient until some years ago (11) . Recent advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents. The anti-tumor necrosis factor α (TNFα) agents (etanercept, infliximab, adalimumab and golimumab) have opened new horizons. These drugs moderate signs and symptoms of inflammation, improve QoL and functional status, and inhibit the progression of structural destruction in peripheral joints (12) (13) (14) (15) . In view of the fact that nowadays drugs able to modify the course of PsA are available, the disease should be early diagnosed and treated. Truly, the major goals of the management, i.e. the decrease of pain intensity, the improvement of function and the prevention of joint injury, can be better achieved by early intervention (16) (17) (18) (19) (20) Table I ). Some trials also showed an effect on dactylitis and enthesitis (24) . Additionally, the anti-TNF agents have been shown to significantly improve measures of fatigue, function and quality of life (25) . No different safety problems from those observed in patients with rheumatoid arthritis have been reported in those with PsA (24) . However, although the occurrence is infrequent, TNF inhibitors are associated with an increased risk of bacterial, viral, invasive fungal and mycobacterial infections, making careful monitoring and early evaluation critical. Data from registry-based longitudinal studies confirmed the effectiveness and longterm safety of anti-TNF therapies in a real life setting (26, 27) . Additionally, anti-TNF therapies are the first with proven efficacy in slowing down or halting radiographic progression (27) . To date, there is no direct head-to-head randomised controlled trial comparing anti-TNF agents. However, by an indirect analysis of placebo-controlled trials no significant differences in the proportion of patients achieving PsARC and ACR 20 or experiencing serious adverse events seem to emerge (23, 24) . As far as skin involvement is concerned, there is evidence for a poor PASI 75 response at 12 weeks for etanercept when compared with the other anti-TNF agents (24) . Since no specific anti-TNF agent has been demonstrated to be more effective than others, the drug choice should be made according to the available safety data, the presence of extra-articular manifestations and the patient's preferences. Indicatively, patients with PsA and uveitis or inflammatory bowel disease should be preferentially treated with a monoclonal antibody, whereas patients at risk of tuberculosis should preferentially receive etanercept. At present, no RCT has been purposely carried out to assess the effectiveness of any anti-TNF therapy in PsA patients with manifestations different from peripheral joint involvement. With regard to spinal disease, only one observational study reported on the effect of etanercept in 32 patients with axial PsA (29) . After a 12-month treatment, a significant improvement of BASDAI was observed in 72% of patients and of BASFI in 68% (29) . Dactylitis and enthesitis were evaluated as secondary end points in some RCTs on golimumab (15) and infliximab (30, 31) . A significant improvement was observed in these studies.
Although there are only few data from registries and observational studies on switching from one TNF-α inhibitor to another in PsA (32) (33) (34) , PsA patients who do not respond or do not tolerate a TNFα blocker are successfully treated with another in clinical practice. The implementation of treatment strategies after failure of one biological agent is needed and, therefore, a preference for a particular TNF inhibitor cannot be established. However, in case of discontinuation due to lack of efficacy, it would be logical to switch to a TNF-α blocker structurally different from the one which failed.
Infliximab is a chimeric (mouse-human) monoclonal antibody specific for soluble and membrane-bound TNFα infused at a dosage of 5 mg/kg body weight over a period of at least 2 hours at weeks 0, 2, and 6 and every 8 weeks thereafter. The efficacy of infliximab has been mainly evaluated in the IMPACT 2 trial enrolling 200 patients with active PsA despite the use of previous DMARDs or NSAIDs (30) . The 14-week data showed that, compared with placebo, infliximab-treated patients had significantly better response rates for ACR 20 (58% vs 11%), PsARC (77% vs 27%), and PASI 75 (64% vs 2%). When compared with the placebo group, fewer patients in the infliximab group had dactylitis (18% vs 30%) or active enthesopathy (22% vs 34%). Disability and quality of life measures were also significantly improved by infliximab treatment compared with placebo. Infliximab was generally well tolerated, with a similar incidence of adverse events in each group (30 (14) . As far as radiographic progression is concerned, the mean change at week 48 from baseline in the modified Sharp score was 0.1 in patients receiving adalimumab for 48 weeks and 1.0 in those receiving placebo for 24 weeks followed by adalimumab for 24 weeks (39). During a 2-year open label extension study, adalimumab showed a good safety profile with no clinically meaningful changes in the occurrence of adverse events (40) .
Golimumab is a fully human IgG1k anti-TNFα antibody generated and affinity-matured in an in vivo system to obtain high affinity and specificity for human TNFα. Golimumab is currently given by subcutaneous injection (50 mg every month), but intravenous administration will be available in future. Its serum half-life was estimated at 2-3 weeks, providing basis for the less frequent administration (monthly) compared to other available subcutaneous TNFα antagonists. The main clinical data were derived from the GO-REVEAL trial that compared golimumab with placebo for the treatment of patients with active PsA despite the use of previous DMARDs or NSAIDs (15) . The 14-week data showed that golimumab 50 mg significantly improved ACR 20 (51% vs 9%), PsARC (73% vs 21%), and PASI 75 (40% vs 3%) compared with placebo. Significant improvement was observed for other major secondary endpoints including HAQ, SF-36, NAPSI, and PsA-modified MASES index. Golimumab was generally well tolerated in this trial (15) . The openlabel extension of the study showed that these beneficial effects were also maintained at 104 weeks. Until now these data have been published only as an abstract (41) . Additionally, PsA patients receiving golimumab showed significantly less progression of the structural joint damage at week 52 of treatment in comparison with those receiving placebo (42) . n REFERENCES
